Unicycive Therapeutics Inc
UNCY4.620USD
0.000
收盘 10/03, 16:00（美东）报价延迟15分钟
65.20M总市值
亏损市盈率 TTM
关于 Unicycive Therapeutics Inc 公司
Unicycive Therapeutics, Inc. 是一家生物技术公司，正在开发某些疾病的治疗方法。其项目专注于肾脏疾病，这是一个有可能带来医疗益处的领域。其开发项目专注于两种新型疗法：Oxylanthanum Carbonate 和 UNI 494。Oxylanthanum Carbonate 是一种新型的试验性磷酸盐结合剂，正在开发用于治疗透析慢性肾脏病患者的高磷血症。UNI-494 是一种受专利保护的新化学实体，正在临床开发中，用于治疗与急性肾损伤相关的疾病。Oxylanthanum Carbonate 和 UNI 494 最初由 Spectrum Pharmaceuticals (Spectrum) 和 Sphaera Pharma 开发并分别获得其许可。
Unicycive Therapeutics Inc简介
公司代码UNCY
公司名称Unicycive Therapeutics Inc
上市日期Jun 17, 2021
CEODr. Shalabh Gupta, M.D.
员工数量22
证券类型Ordinary Share
年结日Jun 17
公司地址4300 El Camino Real, Suite 210
城市LOS ALTOS
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94022
电话16503840642
网址https://unicycive.com/
公司代码UNCY
上市日期Jun 17, 2021
CEODr. Shalabh Gupta, M.D.
Unicycive Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 10月2日 周四
更新时间: 10月2日 周四
持股股东
股东类型
持股股东
持股股东
占比
Vivo Capital, LLC
6.44%
Octagon Capital Advisors LP
5.66%
Nantahala Capital Management, LLC
5.32%
Great Point Partners, LLC
4.51%
The Vanguard Group, Inc.
3.43%
其他
74.64%
持股股东
持股股东
占比
Vivo Capital, LLC
6.44%
Octagon Capital Advisors LP
5.66%
Nantahala Capital Management, LLC
5.32%
Great Point Partners, LLC
4.51%
The Vanguard Group, Inc.
3.43%
其他
74.64%
股东类型
持股股东
占比
Hedge Fund
17.29%
Venture Capital
9.12%
Individual Investor
3.56%
Investment Advisor
3.44%
Investment Advisor/Hedge Fund
0.53%
Research Firm
0.13%
其他
65.94%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
58
5.48M
31.05%
-1.46M
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
2023Q2
42
9.36M
61.47%
-512.55K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Vivo Capital, LLC
1.14M
6.44%
--
--
Jun 30, 2025
Octagon Capital Advisors LP
1.00M
5.66%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
939.20K
5.32%
+3.00
+0.00%
Jun 30, 2025
Great Point Partners, LLC
796.56K
4.51%
-301.44K
-27.45%
Jun 30, 2025
The Vanguard Group, Inc.
605.95K
3.43%
+484.71K
+399.78%
Jun 30, 2025
Gupta (Shalabh K)
597.25K
3.38%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
473.56K
2.68%
-34.33K
-6.76%
Jun 30, 2025
Rosalind Advisors, Inc.
242.49K
1.37%
+242.49K
--
Apr 30, 2025
Acuta Capital Partners, LLC
62.90K
0.36%
-172.39K
-73.27%
Jun 30, 2025
Geode Capital Management, L.L.C.
58.79K
0.33%
+866.00
+1.50%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月2日 周四
更新时间: 10月2日 周四
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
